LAC provides funding to 37 local organizations in support of Canada's documentary heritage
GATINEAU, QC, June 4, 2025 /CNW/ -
This year, archives, museums and documentary heritage institutions will share $1.425 million to carry out 37 projects selected under Library and Archives Canada's (LAC) Documentary Heritage Communities Program (DHCP).
View the projects funded by the DHCP in 2025–2026:
These projects were selected for the significant impact they will have on documentary heritage preservation, and access, and in the broader community. LAC funding empowers local recipient organizations to allocate essential resources to projects aimed at enhancing access and awareness of their collections, while also bolstering their capacity to safeguard Canada's documentary heritage.
Heritage organizations play a vital role in preserving Canada's local memory. LAC is proud to contribute to documenting, preserving and making accessible to the public a memory that reflects Canadian experiences, cultures and society.
About Library and Archives Canada
The mandate of LAC is to acquire and preserve the documentary heritage of Canada for the benefit of present and future generations and to be a source of enduring knowledge accessible to all, contributing to the cultural, social and economic advancement of Canada. LAC also facilitates cooperation among communities involved in the acquisition, preservation and diffusion of knowledge and serves as the continuing memory of the Government of Canada and its institutions.
Quotes
" I would like to congratulate all the recipients this year. I also want to express my gratitude for the outstanding efforts they put forth in educating and informing Canadians about their history. We take pride in supporting these initiatives, which will further empower local institutions and contribute to the development of more resilient communities."
—The Honourable Steven Guilbeault, Minister of Canadian Identity and Culture and Minister responsible for Official Languages
"My heartfelt congratulations to all the recipients! Your dedication to documenting and preserving your community's history is truly commendable. It brings me much joy to see how LAC is able to support amazing projects like yours through yearly funding. Now, more than ever, it's essential for LAC and communities across Canada to stay committed to making our shared stories accessible to everyone."
—Leslie Weir, Librarian and Archivist of Canada
"LAC's DHCP funding was crucial for the ICC Canada Archives in 2024-2025. This funding allowed us to enable access to Inuit documentary heritage in Inuktitut. Inuktitut is a living language and the first language of many Inuit in Canada."
— Lisa Mullins, Archivist, Inuit Circumpolar Council Canada
"The funding from the DHCP has made an immense difference to the organization. In the recordings currently restored and made accessible, there are notable musicians, whose legacy will be remembered."
— Felix Rowe, Administrative officer, National Youth Orchestra of Canada
Quick Facts
Since the creation of the DHCP in 2015, LAC has provided $16.395 million in support of 407 documentary heritage community projects.
This year, of the 37 recipients, 9 organizations will receive funding for Indigenous documentary heritage projects, and nine organizations will receive funding for Francophone documentary heritage projects.
An organization can receive funding of up to $50,000 per year (up to $60,000 for a remote organization) to implement its project.
The next call for proposals to apply for funding will be issued in the fall of 2025.
Associated Links
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
21 minutes ago
- Cision Canada
Ministers of Veterans Affairs and National Defence mark Victory in Asia and the Pacific and the End of Second World War Français
OTTAWA, ON , Aug. 15, 2025 /CNW/ - Today, the Honourable Jill McKnight, Minister of Veterans Affairs and Associate Minister of National Defence, and the Honourable David J. McGuinty, Minister of National Defence, issued the following statement to mark Victory in Asia and the Pacific: "Today, we mark the 80th anniversary of Victory in Asia and the Pacific, when Allied forces brought the Second World War to an end. "While Canada is widely recognized for its fight against tyranny and oppression in Europe and on the Atlantic Ocean, it is less known that more than 10,000 Canadians were also involved in the struggle against Imperial Japan in Asia and the Pacific. In 1941, nearly 2,000 Canadians were sent to help garrison Hong Kong, 800 of whom were either killed or wounded in action, while approximately 260 more died in harsh prisoner-of-war camps. "Thousands of members of the Royal Canadian Air Force served in places like Malaysia, Indonesia, Burma and India. They played critical roles as radar operators and members of bomber, transport, reconnaissance and as fighter squadrons. At home many more supported coastal defence efforts. When the Imperial Japanese Army approached the British Columbia coast in 1942, RCAF squadrons guarded against enemy submarines and aerial attacks. Meanwhile, Royal Canadian Navy sailors saw active service against the Imperial Japanese Navy, with warships escorting convoys across the Pacific and along our west coast, while Canadian Merchant seamen served on Canadian and Allied ships in the region. "Three Canadians—Company Sergeant Major John Robert Osborn, Major Charles Ferguson Hoey and Lieutenant Robert Hampton Gray—were awarded the Victoria Cross posthumously for their bravery while fighting in the Pacific theatre. "On this 80 th anniversary, we encourage Canadians to remember those who served, as we remain eternally grateful to them and the more than 10,000 others from Canada and Newfoundland who helped bring the Second World War finally to an end." Associated links: SOURCE Veterans Affairs Canada - Ottawa
Cision Canada
21 minutes ago
- Cision Canada
Statement by Prime Minister Carney on National Acadian Day Français
OTTAWA, ON, Aug. 15, 2025 /CNW/ - "Today, we celebrate National Acadian Day and honour the courage and resilience of the Acadian people, who have defended their language, culture, and identity for centuries. From Caraquet to Chéticamp, from Bonaventure to Tignish, Acadians have helped shape our country's collective identity. Canada's new government is committed to preserving this heritage – by investing in celebrations of Acadian culture, by supporting Francophone students in minority settings, and by helping Francophone entrepreneurs grow their businesses in Acadian and other minority Francophone communities across the country and beyond. These actions reflect our ambition to build a Canada that is inclusive and proud of the rich traditions of one of the oldest francophone communities in North America." This document is also available at
Cision Canada
21 minutes ago
- Cision Canada
VABYSMO® (faricimab injection) Now Publicly Funded For Macular Edema Secondary to Retinal Vein Occlusion (RVO) and Pre-Filled Syringe (PFS) in Quebec Français
Vabysmo now covered across all three approved indications in the province, providing patients with a comprehensively funded option for their needs MISSISSAUGA, ON, Aug. 15, 2025 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce today that VABYSMO ® (faricimab injection) is now publicly funded for macular edema secondary to retinal vein occlusion (RVO) on the Régie de l'assurance maladie du Québec (RAMQ) list of medications. 1 This latest update also includes funding for Vabysmo in a 6.0 mg single-use pre-filled syringe (PFS), providing an additional option and expanded access for patients in Quebec. Vabysmo received Health Canada authorization for treatment of macular edema secondary to retinal vein occlusion (RVO) in July 2024, and the approval of the PFS format in December 2024. 2 "This expansion in coverage for people with RVO in Quebec is welcome news in our mission to advance eye care and provide innovative solutions for people living with serious retinal conditions," said Carlene Todd, Vice President, Access at Roche Pharmaceuticals Canada. "We are deeply committed to ensuring equitable and timely access to our treatments, ensuring that provinces across the country prioritize access to innovative medicines that will ultimately improve the lives of people impacted by vision loss." With this latest listing, Vabysmo is now covered in Quebec for all three of its indications and in both formats, including neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and the latest, macular edema secondary to retinal vein occlusion (RVO). These leading causes of vision loss affect around 70 million people worldwide and can have a serious impact on patients, their families, and caregivers. 3,4,5,6 "The recent reimbursement for RVO in Quebec is a significant step forward for people living with the condition," said Dr. Ananda (Andy) Kalevar, Associate Professor, Department of Ophthalmology at Sherbrooke University, Quebec. "It gives ophthalmologists a valuable treatment option and provides patients with access to a medication that may ultimately offer the best outcomes for their vision." Roche Canada is committed to continuing to work with remaining provincial jurisdictions to make Vabysmo available through public and private drug plans for those living with RVO. About retinal vein occlusion (RVO) RVO is the second most common cause of vision loss due to retinal vascular conditions. It affects an estimated 28 million adults globally, mainly those aged 60 or older, and can lead to severe and sudden vision loss. 3,7 There are two main types of RVO: branch RVO (BRVO), which affects more than 23 million people globally and occurs when one of the four smaller 'branches' of the main central retinal vein becomes blocked; and central RVO (CRVO), which is less common, affecting more than four million people worldwide, and occurs when the eye's central retinal vein becomes blocked. 3,8 The levels of Vascular Endothelial Growth Factor A (VEGF-A) and angiopoietin-2 (Ang-2) are elevated in RVO and it is thought that their increased expression drives disease progression. 9,10 RVO typically results in sudden, painless vision loss in the affected eye because the vein blockage restricts normal blood flow in the affected retina, resulting in ischemia, bleeding, fluid leakage and retinal swelling called macular edema. 7,11,8 The safety and efficacy of Vabysmo for the treatment of macular edema secondary to retinal vein occlusion (RVO) were assessed in two randomised, multi-centre, double-masked, studies in patients with macular edema secondary to BRVO (BALATON) or CRVO/hemiretinal vein occlusion (HRVO) (COMINO). Between Week 24 and Week 72, for patients who received faricimab Q4W/faricimab PTI, 49% of patients in BALATON and 34% of patients in COMINO completed at least one cycle of every 12 weeks (Q12W) and maintained ≥ Q12W dosing without an interval reduction below Q12W through Week 68; 32% of patients in BALATON and 24% of patients in COMINO completed 2 cycles of Q16W through Week 72. 2 About Vabysmo ® (faricimab injection) Vabysmo is a humanized bispecific immunoglobulin G1 (IgG1) antibody that acts through inhibition of both Ang-2 and vascular endothelial growth factor A (VEGF-A). By inhibiting VEGF-A, faricimab suppresses endothelial cell proliferation, neovascularization and vascular permeability. By inhibiting Ang-2, faricimab is thought to increase vascular stability and desensitize blood vessels to the effects of VEGF-A. Ang-2 levels are increased in some patients with wet AMD, DME, and RVO. 2 In Canada, Vabysmo is authorized for the treatment of neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion (RVO). 2 To date, Vabysmo is approved in more than 100 countries for DME and nAMD, and in over 30 countries for macular edema following retinal vein occlusion (RVO). 12,13,14,15,16,17 About Roche Canada At Roche Canada, patients and science are at the heart of everything we do. Our passion for science and our commitment to relentlessly pursuing the impossible for patients have made us one of the world's leading pharmaceutical, in-vitro diagnostics, and diabetes care management companies. With our combined strength in diagnostics and pharmaceuticals, we're driving healthcare forward, while ensuring we deliver meaningful benefits for patients and sustainable healthcare systems. We are committed to creating a world where we all have more time with the people we love. And we're adding our expertise in new areas, such as artificial intelligence, real world data collection and analysis and collaborating with many different sectors and industries. Having the courage to reinvent ourselves and question the status quo is what patients and healthcare systems expect from Roche - and our commitment is as strong today as it was on the first day of our Canadian journey in 1931. Today, Roche Canada employs nearly 2,000 people at its offices in Mississauga, Ontario, in Laval, Quebec, and across the country from coast to coast to coast. For more information, please visit or follow Roche Canada on LinkedIn. References [1] RAMQ List of medications. Available at: Accessed on August 14, 2025. [2] Vabysmo Product Monograph, July 25, 2025 [3] Song P, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 2019; 9:010427. Song P, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 2019; 9:010427. [4] Yau JWY, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012; 35:556–64. [5] Connolly E, et al. Prevalence of age-related macular degeneration associated genetic risk factors and 4-year progression data in the Irish population. Br J Ophthalmol. 2018;102:1691–95. [6] Bright Focus Foundation. Age-Related Macular Degeneration: Facts & Figures [Internet; cited August 2025]. Available from: Accessed on August 6, 2025. [7] Moorfields Eye Hospital, United Kingdom National Health Service Foundation Trust. RVO [Internet; cited August 2025]. Available from: Accessed on August 6, 2025. [8] Campochiaro P. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015; 49:67-81. [9] Joussen et al. Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye. 2021; 35:1305-1316. [10] Regula JT, et al. Targeting key angiogenic pathways with a bispecific CrossMab optimised for neovascular eye diseases. EMBO Molecular Medicine. 2016; 8:1265–88. [11] Schmidt-Erfurth U, et al. Guidelines for the management of retinal vein occlusion by the European society of retina specialists (EURETINA). Ophthalmologica. 2019; 242:123-162. [12] U.S. Food and Drug Administration (FDA). Highlights of prescribing information, aflibercept 2 mg. 2022. [Internet; cited August 2025]. Available from: Accessed on August 6, 2025. [13] FDA. Highlights of prescribing information, Vabysmo. 2022. [Internet; cited August 2025]. Available from: Accessed on August 6, 2025. [14] FDA approves Genentech's Vabysmo for the treatment of RVO [Internet; cited August 2025]. Available from: Accessed on August 6, 2025 [15] Chugai obtains regulatory approval for Vabysmo, the only bispecific antibody in the ophthalmology field, for additional indication of macular edema associated with RVO. [Internet; cited August 2025]. Available from: Accessed on August 6, 2025. [16] European Medicines Agency. Summary of product characteristics, Vabysmo, 2022 [Internet; cited August 2025]. Available from: Accessed on August 6, 2025. [17] Roche Data on File SOURCE Hoffmann-La Roche Limited (Roche Canada)
